Search

Your search keyword '"Marron, Thomas"' showing total 510 results

Search Constraints

Start Over You searched for: Author "Marron, Thomas" Remove constraint Author: "Marron, Thomas"
510 results on '"Marron, Thomas"'

Search Results

1. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

3. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.

4. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis

5. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

6. Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study

8. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

9. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

10. Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma

11. Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity

12. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

14. Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma

15. TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer

16. Circulating proteins to predict COVID-19 severity

18. Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae

19. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

20. Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

21. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

23. Correction: The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

24. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

25. THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

26. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification

27. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice

29. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells

30. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

31. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

33. Single cell view of tumor microenvironment gradients in pleural mesothelioma

34. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes

35. Efficacy of immune checkpoint inhibitors in patients with HIV-associated unresectable HCC (uHCC): Propensity-score matched analyses from two international consortia.

36. Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study

37. An inflammatory cytokine signature predicts COVID-19 severity and survival

38. A conserved dendritic-cell regulatory program limits antitumour immunity

40. Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children

41. Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

42. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis

43. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

44. 1043 Intratumoral mRNA IL-12 can induce a dose dependent immunostimulatory effect within tumor microenvironment in patients with advanced solid tumors

45. 650 Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer

48. PB2258: PHASE 1 FIRST IN HUMAN STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF GRC54276, A NOVEL HPK1 THRONINE-KINASE INHIBITOR, IN ADVANCED SOLID TUMOURS AND LYMPHOMAS.

49. Qualification of major pathological response as a surrogate endpoint for relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.

50. Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC

Catalog

Books, media, physical & digital resources